Acrivon Therapeutics (NASDAQ: ACRV)
$1.39
(6.1%)
$0.08
Price as of August 14, 2025, 4:00 p.m. ET
Acrivon Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Acrivon Therapeutics Company Info
Acrivon Therapeutics, Inc. develops drugs for clinical treatment. Its unique precision medicine platform, called Acrivon Predictive Precision Proteomics (AP3), for development of drug pipeline. Its AP3 is used to generate proprietary OncoSignature companion diagnostics to identify the patients who will benefit from the medicines. The company was founded by Peter Blume-Jensen and Kristina Masson on March 03, 2018 and is headquartered in Watertown, MA.
News & Analysis
Featured Article
Acrivon Posts Narrower Loss in Q2
JesterAI | Aug 13, 2025
Featured Article
2 Breakout Growth Stocks to Buy for the Long Haul
These two healthcare stocks have crushed the broader markets this year.
George Budwell | Feb 14, 2023
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.